Zetta Genomics, a provider of large-scale genomic data management, has appointed Andy Etheridge as its Director of Strategic Partnerships. Liam White has also been brought in as Head of Product, to develop the company’s XetaBase platform in line with the growing data management needs of the genomics and precision medicine market. The two appointments will accelerate Zetta’s strategic partnerships and growth plans.
Andy was previously Marketing Services Director at IQVIA, a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. With over 30 years’ experience in the healthtech space, and a deep understanding of customer challenges and opportunities, Andy is well placed to lead Zetta Genomics in its next phase of growth.
Liam White also joins Zetta Genomics as Head of Product. His team will work closely with commercial colleagues to develop the company’s pioneering Xetabase platform – informed by the needs and ambitions of its growing global user base. Liam is highly experienced in the genomic technology space, having previously worked in product teams at Congenica and Prenetics. His appointment follows numerous technical hires across the Zetta Genomics team in recent months, in roles including software development, R&D and product commercialisation.
Prioritising strategic partnerships
Since its inception at the University of Cambridge, and within the ground-breaking 100,000 Genomes Project, Zetta Genomics has built strong customer and partner networks which include Microsoft, Fujitsu, Genomics England and the NHS Genomic Medicine Service.
A key priority for Andy and Liam will be to lead a strategic partnership initiative at Zetta Genomics. The initiative will focus on identifying, recruiting and collaborating with partners who offer technologies that complement XetaBase. It will also explore partnerships that offer exciting XetaBase integration options for end users. XetaBase is already compatible with the Microsoft Azure and AWS cloud computing platforms.
The ultimate ambition for Zetta is to scale the availability of precision medicine to patients through the reach of partner organisations – bringing faster and more agile genomic data management to both the clinic and lab. The ultimate promise of precision medicine is quicker diagnoses, more tailored treatment plans and increasingly accurate prognoses – particularly in the fields of oncology and rare disease.
